SEMAGLUTIDE

Semaglutide is a long-acting synthetic glucagon-like peptide-1 receptor agonist (GLP-1 RA) engineered with amino acid substitutions and a C18 fatty diacid chain enabling albumin binding that extends its half-life to approximately one week, enabling once-weekly administration in research and clinical contexts. Its mechanism involves GLP-1 receptor activation in the central nervous system — particularly within hypothalamic circuits — producing satiety signaling, alongside peripheral effects including glucose-dependent insulin secretion, glucagon inhibition, and delayed gastric emptying. Phase 3 clinical data have demonstrated significant body weight reductions over 68 weeks in individuals with obesity, with additional research ongoing in cardiovascular risk reduction, non-alcoholic steatohepatitis, chronic kidney disease, and neurological conditions including Parkinson’s disease. Supplied as lyophilized powder, ≥99% purity. Store at -20°C. Research use only. Not for human consumption.